Incyte to Acquire Vega Therapeutics for Up to $2 Billion, Adding Phase 3 Monoclonal Antibody for Von Willebrand Disease
核心洞察
Incyte has agreed to acquire Vega Therapeutics (搜索), a Star Therapeutics (搜索) subsidiary, for $1.25 billion upfront with up to $750 million in sales milestone payments.
The deal centers on VGA039, a first-in-class, Phase 3 monoclonal antibody targeting Protein S for von Willebrand disease (搜索), the most common inherited bleeding disorder.
VGA039 has the potential to be the first subcutaneous prophylactic therapy with once-monthly dosing, replacing current intravenous infusions required two to three times weekly.
Incyte has entered into a definitive agreement to acquire Vega Therapeutics (搜索), a wholly owned subsidiary of Star Therapeutics (搜索), in a deal valued at up to $2 billion. The transaction adds a late-stage, first-in-class monoclonal antibody candidate to Incyte's hematology portfolio and represents the company's first acquisition under Chief Executive Officer Bill Meury, who took the helm last year.
Under the terms of the stock purchase agreement, Incyte will pay $1.25 billion upfront, with Star Therapeutics (搜索) eligible to receive up to $750 million in additional payments upon the achievement of sales milestones. The transaction, which has been approved by both companies' Boards of Directors, is expected to close in the third quarter of 2026, pending Hart-Scott-Rodino antitrust review and other customary closing conditions.
VGA039: A Novel Mechanism for Bleeding Disorders
The centerpiece of the acquisition is VGA039, an investigational monoclonal antibody that targets Protein S with a dual mechanism of action—promoting platelet attachment and enhancing fibrin deposition to restore hemostasis. The drug is currently in the Phase 3 VIVID-6 study (NCT07115004), a global single-arm cross-over trial designed to investigate the safety and efficacy of subcutaneous administration of VGA039 as prophylaxis for bleeding in patients with all types of von Willebrand disease (搜索) (VWD), including those with a high disease burden.
VGA039 has received Breakthrough Therapy, Fast Track, orphan drug, and rare pediatric disease designations from the U.S. Food and Drug Administration (FDA). Results from the VIVID-6 trial are expected in 2029.
"VGA039 fits directly into our strategy of building a top-tier growth company for the future," said Bill Meury, Chief Executive Officer of Incyte. "It is a first-in-class, Phase 3 asset with compelling early data, a manageable development path and the potential to become an important new growth driver in one of our core therapeutic areas – hematology."
Addressing Unmet Need in Von Willebrand Disease (搜索)
Von Willebrand disease (搜索) is the most common inherited bleeding disorder, affecting approximately 135,000 diagnosed individuals in the United States. The condition, caused by low or defective von Willebrand factor, results in excessive bleeding that can vary in severity and frequency, significantly impacting patients' quality of life and complicating even minor injuries and surgeries.
Current prophylactic treatment options include factor replacement therapies that often require two to three intravenous infusions each week. Limitations to current therapies and underdiagnosis mean that the treated patient population in the U.S. is estimated at only around 35,000 in recent years. VGA039, as a subcutaneously self-administered therapy with a convenient once-monthly dosing regimen, has the potential to meaningfully improve convenience and quality of life for patients while significantly expanding the use of prophylaxis for VWD.
Incyte has characterized the opportunity as a "$1 billion-plus market," with VGA039 positioned to be broadly applicable across different types of VWD and all types of bleeds.
Strategic Rationale for Incyte
The acquisition is part of Incyte's strategy to reduce its reliance on blockbuster drug Jakafi (ruxolitinib), which treats blood cancer and graft-versus-host disease. Jakafi will begin losing patent protection in 2028. Direct Jakafi sales and royalties on the drug sold by Novartis outside the U.S. accounted for approximately $3.5 billion of Incyte's total revenues of $5.1 billion last year.
"This milestone reflects our team's deep commitment to innovation and underscores our strategy to develop first-in-class and best-in-class therapies for serious conditions with high unmet need," said Adam Rosenthal, Ph.D., Founder and Chief Executive Officer of Star Therapeutics (搜索). "VGA039 will be advanced by Incyte, a global biopharmaceutical leader with deep expertise in hematology and a significant commercial track record."
The transaction is structured as an equity acquisition, with Incyte expecting to record an R&D charge of approximately $1.25 billion in the third quarter and full year 2026 GAAP and non-GAAP results. Lazard is serving as financial advisor to Incyte, with Goodwin Procter LLP as legal counsel. Evercore and Morgan Stanley are acting as financial advisors to Star Therapeutics (搜索), with Fenwick & West LLP as legal counsel.